Oral and Non-insulin Injected Hypoglycemic Therapy Utilization Patterns
Completed
Conditions studied: Diabetes Mellitus, Type 2
In brief
This protocol is for a series of descriptive analyses conducted within a cohort of patients using linagliptin, other dipeptidyl peptidase-4 (DPP-4) inhibitors, and other oral and non-insulin injected hypoglycemic medications between May 2011 and July 2012. Understanding 1) the existing utilization patterns for linagliptin, sitagliptin, saxagliptin, and other oral and non-insulin injected hypoglycemic agents and (2) the differences in utilization patterns between these agents will help with the design, analysis and interpretation of comparative effectiveness and safety studies of linagliptin, other DPP-4 inhibitors, and other agents. The study will provide an overview of existing utilization patterns for linagliptin, other dipeptidyl peptidase-4 (DPP-4) inhibitors, other oral and non-insulin injected hypoglycemic agents, in order to detect potential selective prescribing patterns that might lead to channeling bias.
Key facts
- Study ID
- NCT02138097
- Run by
- Boehringer Ingelheim
- People needed
- 615067
- Starts
- 2014-05-01
- Expected to finish
- 2014-08-01
- Last updated by the study team
- 2015-10-06
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- diagnosis of type 2 diabetes mellitus
- a dispensing of an oral or non-insulin injected hypoglycemic medication between May 2011 and June 2012
- at least 6 months enrolment in the database preceding the date of the first dispensing
You may not qualify if…
- age < 18
- missing or ambiguous age or sex information
- at least one diagnosis of type 1 diabetes mellitus or secondary diabetes
Where it is running
- 1218.161.1 Boehringer Ingelheim Investigational Site — Boston, Massachusetts, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.